Canntab Therapeutics — Investor Presentation (September 2020)
15 slides from Canntab Therapeutics's investor presentation, Sep 20, 2020
Slide 1: Corporate Presentation
CORPORATE PRESENTATION CSE: PILL | OTCQB: CTABF | FSE:TBF1 CSE: PILL | OTCQB: CTABF | FSE:TBF1 September 2020 Canntab Therapeutics Limited © 2020
Slide 2: Disclaimer
DISCLAIMER This presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "b
Slide 3: What We Do
WHAT WE DO Canntab Therapeutics is the industry leader in solid oral dose formulations of cannabis with a product line of cannabinoid (THC & CBD) and terpenoid blends in exacting dosages. With one US Patent granted on September 17th of this year, and 13 more patents pending in Canada and the United
Slide 4: What's Happening Now
WHAT’S HAPPENING NOW We received our Cannabis Licence, (Processing - Standard, Federal Sales - Medical). We cleared the 60 days notice period after submitting our Notice of New Cannabis Product. Full scale hard pill manufacturing has begun at our facility in Markham, Ontario. We received a U
Slide 5: Strong IP Portfolio
STRONG IP PORTFOLIO 1 US patent granted, with 13 more patents pending in the United States and Canada covering our proprietary processes and hard pill formulations for, Extended Release Sustained Release Instant Release In August 2019, the Geneva-based International Preliminary Report on Paten
Slide 6: Proprietary Process
PROPRIETARY PROCESS Our patent pending proprietary processes allows us to create hard pill formulations that starts with cannabis oil in water emulsions, a unique process in the industry to date. Oil emulsion >> wet granulation >> dried granulation >> blending >> tablet pressing >> coating OUR INNOV
Slide 7: Meeting Medical Standards
MEETING MEDICAL STANDARDS Current delivery mechanisms such as smoking or vaping cannabis, consuming edibles, gel caps, oils and tincture (droppers) do not provide the medical community, including Doctors, patients or the average consumer, with an attractive and professional cannabis solution. CANNTA
Slide 8: Therapeutic Window
THERAPEUTIC WINDOW Smoking cannabis can result in a large initial dose of the drug followed by a precipitous drop. Edibles dosing is unpredictable, making it difficult to maintain therapeutic relief. Our solution, an extended release (XR) tablets with flash melt technology, quickly brings the patien
Slide 9: How We Generate Revenue
HOW WE GENERATE REVENUE WHITE LABELLING LICENSING Q4 2020 HARD PILL MANUFACTURING PRODUCT SALES PROFIT Q4 2020 Q4 2020 ONLINE STORE CBD FROM HEMP SALES CULTIVATED & Q4 2020 EXTRACTED Canntab Therapeutics Limited © 2020 9
Slide 10: Approaching the Opioid Crisis
APPROACHING THE OPIOID CRISIS The opioid crisis claimed 4,588 Canadians in 2018. That’s approximately 1 life lost every 2 hours1. Almost 2 million people filled over 9 million prescriptions for opioids in Ontario, in 2015/20162. Canntab will conduct a clinical study in Q1 2021 with leading orthopedi
Slide 11: Tablet Economics
TABLET ECONOMICS Note: Sensitivity Analysis is meant to be illustrative and is not intended to used as a forecast. Canntab Therapeutics Limited © 2020 11
Slide 12: Capitalization
CAPITALIZATION MAINTAINING ZERO DEBT AND ONLY 30 DAYS OF TRADE PAYABLES Canntab Therapeutics Limited © 2020 12
Slide 13: Looking at the Future
LOOKING AT THE FUTURE Clinical trial with Dr. Garbuz at UBC to investigate potentially opioid sparing CBD/THC formulations in Q1 2021, as we work towards acquiring Drug Identification Numbers (DINs). Q4 release of our new online platform and online store, to include a telehealth department that
Slide 14: Management Team
MANAGEMENT TEAM Jeff Renwick, Co-Founder Richard Goldstein, Co-Founder President & Head of Production Chief Financial Officer Former President/CEO of Orbus Pharma Founder First Republic Capital, Co-Founder Fraser McKenzie, former EVP/Head of IB at Standard Business Development for Indukern Che
Slide 15: Contact Us
CONTACT US Richard Goldstein Chief Financial Officer (647) 209-3279 Richard@Canntab.ca Larry Latowsky Chief Executive Officer (416) 458-6491 Larry@Canntab.ca Canntab Therapeutics Limited © 2020 15
Canntab Therapeutics — Investor Presentation (September 2020) on 6ix